Close Menu

Infectious Disease

News on research and diagnostic development for pathogenic diseases.

The firm plans to submit an EUA application for its quantitative Sanger sequencing COVID-19 test, which could run on hundreds of available CE instruments.

The assays detect either SARS-CoV-2 antigens or antibodies to SARS-CoV-2 to identify active infections and previous exposure.

PharmaCyte, which develops therapies for cancer and diabetes, will be responsible for development and commercialization of tests based on the technology.

The collaboration includes setting up a new testing laboratory that will investigate the use of alternative chemical reagents for test kits.

Avacta said it is aiming to complete development of Affimer reagents for the COVID-19 test by the end of May.